Biotech
Commented by Armin Schulz on March 9th, 2026 | 07:05 CET
Top Dividend Stocks: With Novo Nordisk, RE Royalties, and SAP, investors reap where others only see risk
Markets are currently oscillating between fears of war and hopes for interest rate cuts. While geopolitics and economic data continue to fuel uncertainty, many investors are turning back to a proven principle: reliable dividends. March 2026 highlights how fragile global growth can be when the Strait of Hormuz turns into a geopolitical powder keg and even the IMF warns of new economic shocks. In this tense environment between acute crisis and the search for stable returns, companies with dependable dividend policies are gaining importance. Against this backdrop, we take a closer look at Novo Nordisk, whose dividend stability must prove itself in an increasingly competitive pharmaceutical market, RE Royalties, which offers a remarkably high yield, and SAP, which recently surprised investors with a dividend increase.
Read
Commented by Nico Popp on March 3rd, 2026 | 07:40 CET
Paradigm shift in oncological dermatology: Vidac Pharma as an innovator, what are Almirall and Biofrontera doing?
Oncological dermatology is on the cusp of a revolution that could fundamentally change our understanding of cancer treatment. Persistence Market Research estimates that the global market for the treatment of actinic keratosis will reach a volume of around USD 7 billion by 2026. Analysts expect the market to grow to between USD 11.1 and 14.45 billion by the mid-2030s. This momentum is driven by the aging global population, cumulative UV exposure due to changing leisure habits, and increased awareness of the dangers of skin cancer. Currently, established industry giants such as Almirall and Biofrontera dominate the standard of care for actinic keratosis with their proven products. However, Vidac Pharma marks the transition from merely combating symptoms to a revolutionary procedure in oncological dermatology. This makes the company an opportunity for growth-oriented investors seeking access to a completely new class of drugs in the field of metabolic oncology.
Read
Commented by Fabian Lorenz on March 2nd, 2026 | 07:20 CET
Will the Iran conflict fuel gold prices? Iamgold and Lahontan Gold stand to benefit! Novo Nordisk shares poised for a rebound?
Will tensions in Iran push gold to new highs? At the very least, the crisis currency is likely to see renewed demand, and with it, gold stocks. Iamgold demonstrates that industry does not necessarily rely on rising gold prices to generate strong profits. Expectations for the gold producer's quarterly figures were high. Can the 50% rally continue? Lahontan Gold is currently in a pivotal phase. Its historical resource of just under 2 million ounces is expected to increase following updated estimates. In addition, the construction of the first mine in the heart of the US gold region appears increasingly likely. This may be one of the last opportunities to accumulate the stock at an attractive price. By contrast, Novo Nordisk has lost considerable investor confidence. The shares appear inexpensive, but is another guidance cut looming? Some analysts believe the stock may have already found a bottom.
Read
Commented by Armin Schulz on February 17th, 2026 | 08:10 CET
Cancer Research as a Growth Driver: How Bayer, Vidac Pharma, and Pfizer can enrich your portfolio
Oncology will be put to the test for the pharmaceutical industry in 2026. Never before have so many highly specialized active ingredients been on the verge of market launch at the same time. While checkpoint inhibitors and targeted therapies are revolutionizing treatment, business models are shifting from broad-based approaches to precision medicine. But the reality remains complex: between medical advances, narrow patient groups, and pressure on prices, companies need to readjust. Current developments at Bayer, Vidac Pharma, and Pfizer show how three players with different strategies are responding to this change.
Read
Commented by Fabian Lorenz on February 10th, 2026 | 11:20 CET
SHARE PRICE FIREWORKS! RENK and Novo Nordisk shares take off! Vidac Pharma next?
Share price fireworks at Novo Nordisk yesterday. The battered pharmaceutical stock rose by around 6%. After a weak outlook and the prospect of increasing competition for its blockbuster product, there was some positive news for a change: a competing product is not permitted to be sold in the key US market. RENK shares also rose significantly yesterday. Since last Thursday, the share price has risen by over 10%. Positive analyst commentary is increasing. Vidac Pharma is poised for a rally. The biotech company is working on an attractive oncology pipeline, has once again secured an important patent, and the stock is receiving tailwinds from its Xetra listing. Analysts see the potential for a multiplication.
Read
Commented by Armin Schulz on February 6th, 2026 | 07:00 CET
Almonty Industries Surges, Novo Nordisk and PayPal Correct: Where Are the Entry Points?
The stock market is increasingly divided. While mining stocks are benefiting from geopolitical upheavals and the strategic race for raw materials, established market heavyweights are being punished at the slightest disappointment. This shift reflects the growing limits of globalization. Today, resilience beats efficiency. Three very different companies illustrate this new environment: tungsten producer Almonty Industries, pharmaceutical giant Novo Nordisk, and payment service provider PayPal. We analyze the current situation.
Read
Commented by Fabian Lorenz on February 5th, 2026 | 08:25 CET
Almonty shares are skyrocketing! Novo Nordisk shares are plummeting! And what is Hensoldt doing?
Almonty shares gained over 17% on the Nasdaq on Tuesday. The largest Western tungsten producer is likely to benefit from the US government's build-up of strategic reserves of critical raw materials. In addition, analysts have significantly raised their price target and expect Almonty to achieve a net margin of around 50% in 2027. Novo Nordisk, on the other hand, plummeted by over 17% yesterday. The pharmaceutical company has once again shocked the stock market. It expects declining revenue and profits for the current year. And what about Hensoldt? The stock is treading water, but analysts see potential for price gains. In addition, the company has landed an order worth hundreds of millions of euros.
Read
Commented by Fabian Lorenz on February 4th, 2026 | 08:50 CET
Yesterday +10%! Top news drives shares of Evotec, Novo Nordisk, and CHAR Technologies!
Evotec shares jumped, climbing more than 10% as analysts pushed the stock higher. Does this signal that the turnaround is finally happening, or does Deutsche Bank still have the final say? Strong news also for CHAR Technologies: the Canadian company is launching commercialization of its unique technology for producing biochar and renewable natural gas substitutes from biogenic waste materials. For the expansion, it has secured strong partners, including steel giant ArcelorMittal and the Canadian BMI Group. And what is Novo Nordisk doing? The Danish company presented positive study results for its successor to Wegovy. However, analysts are not exactly thrilled.
Read
Commented by André Will-Laudien on February 4th, 2026 | 07:10 CET
Starting signal! Biotech sector benefits from rotation! Keep an eye on Evotec, Bayer, Vidac Pharma, and BioNTech
The stock market has started 2026 on a positive note. The mining and commodities sector recently proved that return opportunities are not limited to the technology sector, with several stocks doubling in price and a few even increasing tenfold. A breath of fresh air is needed, because other sectors also want to enjoy the stock market spring. Life science stocks have indeed taken a break for almost three years. But now they are back! After a long period of silence, selected companies are showing the first signs of a technical recovery. For investors with a penchant for opportunities and timing, now is the time to rethink old strategies and realign portfolios. In cancer research, recent breakthroughs in personalized immunotherapies have significantly increased the prospects of success for clinical trials. We take a closer look.
Read
Commented by Armin Schulz on February 3rd, 2026 | 07:05 CET
Zinc boom, turnaround, and biotech growth: How to profit with Pasinex Resources, Puma, and Evotec
In volatile markets, investors are looking for exceptional opportunities. Three companies stand out in this regard. A commodities company with exceptional zinc projects, a sporting goods manufacturer undergoing radical transformation, and a biotech pioneer with a unique platform model. The combination of momentum, strategic turnaround, and long-term growth promises attractive return opportunities. We analyse the promising prospects of Pasinex Resources, Puma, and Evotec.
Read